Across TCGA pan-cancer cohorts, HSD17B11 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated HSD17B11 data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher HSD17B11 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated HSD17B11 expression acts as an unfavorable survival marker.

LUSC, BLCA, and UCEC are the cancer types where HSD17B11 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	II,III,IV	0.002	0.743	<.001	24	view →
BLCA	OS	Median	All	0.090	0.688	<.001	18	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	OS	Median	All	0.210	0.781	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: HSD17B11 tumor-vs-normal RNA expression · all HSD17B11 data types